In the wake of concerns over the safety of foreign-made medicines, the US Food and Drug Administration significantly increased the number of inspections of overseas facilities. Yet the agency has failed to assess the extent to which its efforts are actually improving the quality of drugs entering the country, according to a new report by the US Government Accountability Office.

The GAO noted that nearly 40 percent of finished drugs and about 80 percent of active pharmaceutical ingredients are made in facilities that are registered in more than 150 countries. And by some measures, the FDA has made progress – the agency has reduced the number of facilities that have gone without an inspection history to 33 percent of foreign establishments, compared to 64 percent in 2010.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy